You need JavaScript to view this

Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma

Abstract

Introduction. The aim of this model study was to estimate and compare the risk of radiation-induced adverse late effects in pediatric patients with medulloblastoma (MB) treated with either three-dimensional conformal radiotherapy (3D CRT), inversely-optimized arc therapy (RapidArc (RA)) or spot-scanned intensity-modulated proton therapy (IMPT). The aim was also to find dose-volume toxicity parameters relevant to children undergoing RT to be used in the inverse planning of RA and IMPT, and to use in the risk estimations. Material and methods. Treatment plans were created for all three techniques on 10 pediatric patients that have been treated with craniospinal irradiation (CSI) at our institution in 2007-2009. Plans were generated for two prescription CSI doses, 23.4 Gy and 36 Gy. Risk estimates were based on childhood cancer survivor data when available and secondary cancer (SC) risks were estimated as a function of age at exposure and attained age according to the organ-equivalent dose (OED) concept. Results. Estimates of SC risk was higher for the RA plans and differentiable from the estimates for 3D CRT at attained ages above 40 years. The risk of developing heart failure, hearing loss, hypothyroidism and xerostomia was highest for the 3D CRT plans. The risks of all adverse  More>>
Authors:
Brodin, N Patrik; [1]  Niels Bohr Inst., Faculty of Sciences, Univ. of Copenhagen (Denmark)), e-mail: brodin.patrik@gmail.com; Munck af Rosenschoeld, Per; Aznar, Marianne C; Vogelius, Ivan R; [1]  Kiil-Berthelsen, Anne; [1]  Dept. of Clinical Physiology and Nuclear Medicine, Centre of Diagnostic Investigations, Rigshospitalet, Univ. of Copenhagen (Denmark)); Nilsson, Per; Bjoerk-Eriksson, Thomas; [2]  Lannering, Birgitta [3] 
  1. Radiation Medicine Research Center, Dept. of Radiation Oncology, Rigshospitalet, Univ. of Copenhagen (Denmark)
  2. Dept. of Oncology, Skaane Univ. Hospital and Lund Univ., Lund (Sweden)
  3. Dept. of Paediatric Oncology, The Queen Silvia Children's Hospital, Gothenburg (Sweden)
Publication Date:
Aug 15, 2011
Product Type:
Journal Article
Resource Relation:
Journal Name: Acta Oncologica (Stockholm) (online); Journal Volume: 50; Journal Issue: 6; Other Information: 10.3109/0284186X.2011.582514
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; PROTONS; PHOTONS; RADIOTHERAPY; PEDIATRICS; NEOPLASMS; BRAIN
OSTI ID:
1032551
Country of Origin:
Sweden
Language:
English
Other Identifying Numbers:
Journal ID: ISSN 1651-226X; TRN: SE1208020
Availability:
Available from DOI: http://dx.doi.org/10.3109/0284186X.2011.582514
Submitting Site:
SWDN
Size:
page(s) 806-816
Announcement Date:
Jan 09, 2012

Citation Formats

Brodin, N Patrik, Niels Bohr Inst., Faculty of Sciences, Univ. of Copenhagen (Denmark)), e-mail: brodin.patrik@gmail.com, Munck af Rosenschoeld, Per, Aznar, Marianne C, Vogelius, Ivan R, Kiil-Berthelsen, Anne, Dept. of Clinical Physiology and Nuclear Medicine, Centre of Diagnostic Investigations, Rigshospitalet, Univ. of Copenhagen (Denmark)), Nilsson, Per, Bjoerk-Eriksson, Thomas, and Lannering, Birgitta. Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. Sweden: N. p., 2011. Web. doi:10.3109/0284186X.2011.582514.
Brodin, N Patrik, Niels Bohr Inst., Faculty of Sciences, Univ. of Copenhagen (Denmark)), e-mail: brodin.patrik@gmail.com, Munck af Rosenschoeld, Per, Aznar, Marianne C, Vogelius, Ivan R, Kiil-Berthelsen, Anne, Dept. of Clinical Physiology and Nuclear Medicine, Centre of Diagnostic Investigations, Rigshospitalet, Univ. of Copenhagen (Denmark)), Nilsson, Per, Bjoerk-Eriksson, Thomas, & Lannering, Birgitta. Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. Sweden. https://doi.org/10.3109/0284186X.2011.582514
Brodin, N Patrik, Niels Bohr Inst., Faculty of Sciences, Univ. of Copenhagen (Denmark)), e-mail: brodin.patrik@gmail.com, Munck af Rosenschoeld, Per, Aznar, Marianne C, Vogelius, Ivan R, Kiil-Berthelsen, Anne, Dept. of Clinical Physiology and Nuclear Medicine, Centre of Diagnostic Investigations, Rigshospitalet, Univ. of Copenhagen (Denmark)), Nilsson, Per, Bjoerk-Eriksson, Thomas, and Lannering, Birgitta. 2011. "Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma." Sweden. https://doi.org/10.3109/0284186X.2011.582514.
@misc{etde_1032551,
title = {Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma}
author = {Brodin, N Patrik, Niels Bohr Inst., Faculty of Sciences, Univ. of Copenhagen (Denmark)), e-mail: brodin.patrik@gmail.com, Munck af Rosenschoeld, Per, Aznar, Marianne C, Vogelius, Ivan R, Kiil-Berthelsen, Anne, Dept. of Clinical Physiology and Nuclear Medicine, Centre of Diagnostic Investigations, Rigshospitalet, Univ. of Copenhagen (Denmark)), Nilsson, Per, Bjoerk-Eriksson, Thomas, and Lannering, Birgitta}
abstractNote = {Introduction. The aim of this model study was to estimate and compare the risk of radiation-induced adverse late effects in pediatric patients with medulloblastoma (MB) treated with either three-dimensional conformal radiotherapy (3D CRT), inversely-optimized arc therapy (RapidArc (RA)) or spot-scanned intensity-modulated proton therapy (IMPT). The aim was also to find dose-volume toxicity parameters relevant to children undergoing RT to be used in the inverse planning of RA and IMPT, and to use in the risk estimations. Material and methods. Treatment plans were created for all three techniques on 10 pediatric patients that have been treated with craniospinal irradiation (CSI) at our institution in 2007-2009. Plans were generated for two prescription CSI doses, 23.4 Gy and 36 Gy. Risk estimates were based on childhood cancer survivor data when available and secondary cancer (SC) risks were estimated as a function of age at exposure and attained age according to the organ-equivalent dose (OED) concept. Results. Estimates of SC risk was higher for the RA plans and differentiable from the estimates for 3D CRT at attained ages above 40 years. The risk of developing heart failure, hearing loss, hypothyroidism and xerostomia was highest for the 3D CRT plans. The risks of all adverse effects were estimated as lowest for the IMPT plans, even when including secondary neutron (SN) irradiation with high values of the neutron radiation weighting factors (WR{sub neutron}). Conclusions. When comparing RA and 3D CRT treatment for pediatric MB it is a matter of comparing higher SC risk against higher risks of non-cancer adverse events. Considering time until onset of the different complications is necessary to fully assess patient benefit in such a comparison. The IMPT plans, including SN dose contribution, compared favorably to the photon techniques in terms of all radiobiological risk estimates}
doi = {10.3109/0284186X.2011.582514}
journal = []
issue = {6}
volume = {50}
place = {Sweden}
year = {2011}
month = {Aug}
}